ArticleThrombosis journal2026
Anticoagulation therapy for Lemierre syndrome: a comprehensive review and individual participant data analysis.
Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Excision of the internal jugular vein in uncontrolled Lemierre's syndrome: a case report and literature review.Oral and maxillofacial surgery · 2026Review
- Expanding the clinical spectrum of Lemierre syndrome and Lemierre-like septic internal jugular vein thrombophlebitis: a four-case series.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLemierre's syndrome is a life-threatening infection characterized by septic thrombophlebitis of the internal jugular vein and septic embolism. Antimicrobial therapy is an established treatment for Lemierre's syndrome; however, its role in anticoagulation therapy remains unclear.
objectiveTo evaluate the association between anticoagulation therapy initiated concurrently with antimicrobial therapy and the clinical outcomes in patients with Lemierre syndrome.
methodsWe comprehensively searched the PubMed, Embase, and Ichushi databases for case reports, case series, and cohort studies. Lemierre syndrome was defined as (1) a preceding oropharyngeal infection and (2) internal jugular vein thrombophlebitis or septic pulmonary emboli confirmed by imaging or pathology. We performed a case-control analysis and estimated odds ratios using multivariate logistic regression after adjusting for potential confounders.
resultsOf the 2051 screened records, internal jugular vein thrombus progressed in 15 patients (7.18% [15/209]) who received anticoagulation therapy and in 21 patients (18.8% [21/112]) who did not. The median age of the patients was 25 years (interquartile range, 18-45 years), and the baseline characteristics were generally balanced between the anticoagulated and non-anticoagulated patients. For the primary outcome of thrombus progression, anticoagulation therapy was associated with a significantly lower risk compared with no anticoagulation therapy (multiple imputation odds ratio 0.34, 95% CI 0.16-0.70). We observed no clear differences in the incidence of new septic pulmonary emboli (multiple imputation odds ratio 0.45, 95% CI 0.18-1.13) or major bleeding events (multiple imputation odds ratio 1.50, 95% CI 0.44-5.08).
conclusionOur study suggests that although anticoagulation therapy is associated with a significantly reduced risk of IJV thrombus progression, it does not confer a clear benefit for other clinically important outcomes, such as new septic pulmonary emboli or mortality. Therefore, routine initiation of anticoagulation therapy may not be supported for Lemierre syndrome, particularly when the thrombus is limited to the internal jugular vein. Further well-designed observational studies are warranted. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.